Some analysts wanted to know what Lilly's Plan B is, given the fresh wave of generic competition that's about to hit its biggest franchise. What happens if Lilly's current crop of late-stage drugs--frequently touted at the top as one of the biggest and best in the industry--fails to deliver soon?
The litany of clinical trial failures for Eli Lilly's pipeline programs is likely to force the company to start carving up its R&D budget as the pharma giant enters a 7-year drought on the sales side.
The litany of clinical trial failures for Eli Lilly's pipeline programs is likely to force the company to start carving up its R&D budget as the pharma giant enters a 7-year drought on the sales side, according to a group of analysts tracked by the Indianapolis Business Journal.
Eli Lilly has signed on to collaborate on fruquintinib, committing to a package of $86.5 million in fees and milestones to partner on a tumor treatment which was put up on the deal table earlier this year.
Two former Eli Lilly scientists stand accused of passing laboratory trade secrets to a Chinese drugmaker. Guoqing Cao and Shuyu "Dan" Li are held without bail in Indiana, where they were indicted on charges of stealing Lilly's research info to share with Shanghai-based Jiangsu Hengrui Medicine Co.
Meeting next year's minimum revenue goal of $20 billion will be "challenging," Eli Lilly says, and analysts are already speculating about "savage" cost cuts if R&D doesn't come through as Lilly hopes.
Eli Lilly rattled analysts today with a cautionary note on some growing market pressures that will make it difficult to hit its $20 billion revenue projection for 2014, which is intended to be its trough year as generic competition combined with a long drought of meaningful new drug approvals combine to take a heavy toll.
The regulators in charge of Medicare recently dealt Eli Lilly a setback when they adamantly refused to reimburse for the Alzheimer's imaging agent Amyvid in all but a handful of cases.
The Centers for Medicare & Medicaid Services' final decision on Eli Lilly's Alzheimer's imaging agent Amyvid, after appeals from Lilly and patient groups, is that Medicare won't pay for Amyvid-aided brain scans outside of clinical trials.
The Centers for Medicare and Medicaid Services sees little benefit in using PET scans to detect beta-amyloid buildups in dementia patients, and the agency has declined to cover the procedure as a diagnostic, a blow to companies like GE Healthcare, Eli Lilly and Navidea.